NEW YORK (MedscapeWire) May 03
In 2 independent, randomized trials described in the April issue of the Journal of the American Academy of Dermatology, topical pimecrolimus was safe and effective in treating atopic dermatitis in children and adolescents. “The ascomycin derivative pimecrolimus (ASM 981) is a cell-selective cytokine inhibitor, specifically developed for the treatment of inflammatory skin diseases,” write Lawrence F. Eichenfield, MD, from the University of California, San Diego, and colleagues. “Pimecrolimus cream 1% had a rapid onset of action, with significant effects observed within the first week of treatment.” In 2 independent 6-week, multicenter studies of identical design, investigators pooled data from 403 children with predominantly moderate atopic dermatitis randomized to treatment with topical pimecrolimus cream 1% or vehicle. At 8 days after initial application of the study medication, relief of pruritus was significantly better in the pimecrolimus-treated group. At each subsequent evaluation, pimecrolimus-treated patients showed significant improvement compared with controls in all efficacy measures, including Investigator’s Global Assessment score, Eczema Area, Severity Index, and patients’ subjective ratings.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!